At­trac­tive M&A op­tions? An­a­lysts break down what's hot right now

With the num­ber of bio­phar­ma ac­qui­si­tions in 2022 so far falling be­low re­cent years, the in­vest­ment bank SVB Se­cu­ri­ties on Sun­day pub­lished a new re­port on M&A and where there may be some ac­tion in the near term.

As far as the ac­quir­ers, the re­port notes that large bio­phar­ma com­pa­nies’ ex­ecs have a “broad ap­petite for M&A and BD,” and com­pa­nies like Pfiz­er and John­son & John­son are both car­ry­ing cash bal­ances of about $33 bil­lion each as of June 30, while oth­er com­pa­nies like No­var­tis with $20 bil­lion, and Bris­tol My­ers Squibb with $13 bil­lion, can take the lead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER